EP2912036A1 — Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
Assigned to Pfizer Ltd Great Britain · Expires 2015-09-02 · 11y expired
What this patent protects
The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
USPTO Abstract
The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
Drugs covered by this patent
- Zelboraf (vemurafenib) · Hoffmann La Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.